BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23974320)

  • 1. Temozolomide stability in extemporaneously compounded oral suspensions.
    Trissel LA; Zhang Y; Koontz SE
    Int J Pharm Compd; 2006; 10(5):396-9. PubMed ID: 23974320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naratriptan hydrochloride in extemporaneosly compounded oral suspensions.
    Zhang YP; Trissel LA; Fox JL
    Int J Pharm Compd; 2000; 4(1):69-71. PubMed ID: 23985892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations.
    Sidhom MB; Rivera N; Almoazen H; Taft DR; Kirschenbaum HL
    Int J Pharm Compd; 2005; 9(5):402-6. PubMed ID: 23925139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of two concentrations of tiagabine in an extemporaneously compounded suspension.
    Haase MR; Khan MA; Bonilla J
    Int J Pharm Compd; 2003; 7(6):485-9. PubMed ID: 23979810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of extemporaneously prepared cinacalcet oral suspensions.
    Thomson K; Hutchinson DJ; Chablani L
    Am J Health Syst Pharm; 2018 May; 75(9):e236-e240. PubMed ID: 29691267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of an extemporaneous alcohol-free melatonin suspension.
    Johnson CE; Cober MP; Thome T; Rouse E
    Am J Health Syst Pharm; 2011 Mar; 68(5):420-3. PubMed ID: 21330684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of extemporaneously prepared rufinamide oral suspensions.
    Hutchinson DJ; Liou Y; Best R; Zhao F
    Ann Pharmacother; 2010 Mar; 44(3):462-5. PubMed ID: 20150505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of extemporaneously prepared glycopyrrolate oral suspensions.
    Cober MP; Johnson CE; Sudekum D; Penprase K
    Am J Health Syst Pharm; 2011 May; 68(9):843-5. PubMed ID: 21515869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension.
    Cober MP; Johnson CE
    Am J Health Syst Pharm; 2007 Mar; 64(6):644-6. PubMed ID: 17353574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of extemporaneously prepared oxandrolone oral suspensions.
    Johnson CE; Cober MP; Hawkins KA; Julian JD
    Am J Health Syst Pharm; 2011 Mar; 68(6):519-21. PubMed ID: 21378300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
    Li Q; Liu Z; Kolli S; Wetz K; Griffith N; Poi MJ
    Am J Health Syst Pharm; 2016 Sep; 73(17):1331-7. PubMed ID: 27543577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of rifabutin in two extemporaneously compounded oral liquids.
    Haslam JL; Egodage KL; Chen Y; Rajewski RA; Stella V
    Am J Health Syst Pharm; 1999 Feb; 56(4):333-6. PubMed ID: 10690216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of extemporaneously prepared rifaximin oral suspensions.
    Cober MP; Johnson CE; Lee J; Currie K
    Am J Health Syst Pharm; 2010 Feb; 67(4):287-9. PubMed ID: 20133533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of ciprofloxacin in an extemporaneous oral liquid dosage form.
    Johnson CE; Wong DV; Hoppe HL; Bhatt-Mehta V
    Int J Pharm Compd; 1998; 2(4):314-7. PubMed ID: 23989641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions.
    Caruthers RL; Johnson CE
    Am J Health Syst Pharm; 2007 Jul; 64(14):1513-5. PubMed ID: 17617502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1998 Sep; 55(17):1804-9. PubMed ID: 9775343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children.
    Pramann LA; Davidow LW; van Haandel L; Funk RS
    Int J Pharm Compd; 2016; 20(3):257-261. PubMed ID: 28333668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of levetiracetam in extemporaneously compounded suspensions.
    Ensom MH; Decarie D; Rudolph S
    Can J Hosp Pharm; 2011 May; 64(3):207-11. PubMed ID: 22479056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability study of oral pediatric idebenone suspensions.
    Schlatter J; Bourguignon E; Majoul E; Kabiche S; Balde IB; Cisternino S; Fontan JE
    Pharm Dev Technol; 2017 Mar; 22(2):296-299. PubMed ID: 27583702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.